1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Miravant Medical Technologies Inc.

Miravant Medical Technologies Inc.

MRVT
Miravant Medical Technologies Inc.US flagOther OTC
0.00
USD
+0.00
- -
113,571.00Market Cap
1994 Y
1995 Y
1996 Y
1997 Y
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
TTM
Revenue per Share
0.01
0.05
0.31
0.18
0.71
0.82
0.25
0.25
0.02
- -
- -
- -
Basic EPS, GAAP
-1.04
-1.19
-1.37
-2.36
-1.94
-1.25
-1.42
-0.88
-0.78
-0.3
-0.48
-0.41
Free Cash Flow per Basic Share
-0.89
-0.8
-1.61
-2.29
-1.69
-1.06
-0.75
-0.83
-0.42
-0.45
-0.35
-0.31
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.5
-3.51
-4.29
-6.32
-7.53
1.21
0.09
-0.65
-0.45
-0.26
-0.13
-0.36
Tangible Book Value per Share
0.02
0.83
4.81
6.83
1.28
0.83
-0.05
-0.79
-0.54
-0.31
-0.18
-0.39
Basic Weighted Avg Shares
9
10
12
13
14
18
18
19
21
25
33
37
Sales/Revenue/Turnover
- -
- -
4
2
10
15
5
5
- -
- -
- -
- -
Operating Margin (%)
-9,300
-2,380
-513.89
-1,392.54
-280.39
-155.35
-470.8
-334.12
-3,057.11
- -
- -
- -
Depreciation Expense
2
3
3
3
5
4
3
2
2
1
- -
- -
Net Income, GAAP
-10
-12
-16
-30
-28
-22
-26
-16
-16
-7
-16
-15
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-9,500
-2,340
-447.22
-1,325.72
-275.49
-152.68
-565.93
-350.25
-3,198.4
- -
- -
- -
Working Capital
-1
6
52
81
11
25
19
9
-6
-1
5
-2
LT Debt
1
- -
- -
- -
- -
15
25
27
7
7
8
4
Total Equity
- -
8
57
88
20
16
- -
-14
-10
-7
-2
-5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
-223.77
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'05
Jun'05
Sep'05
ST Debt
- -
- -
3
LT Borrowings
8
7
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
3
9
9
Shares Outstanding
37
38
38
Market Capitalization
30
19
14

Working Capital

FRC

•

in mil. unless spec.
Mar'05
Jun'05
Sep'05
Total Current Assets
3
8
4
Cash, Cash Equivalents & STI
3
8
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
3
6
Payables & Accruals
2
3
3
ST Debt
- -
- -
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,263.11%
1,616.67%
-71.79%
Free Cash Flow
12.77%
-5.07%
3.54%
Net Income, GAAP
15.75%
7.38%
112.94%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
- -
- -
- -
- -
- -
2004
- -
- -
- -
- -
- -
2005
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
-0.14
-0.15
0.05
- -
-0.3
2004
-0.2
-0.11
-0.1
- -
-0.48
2005
-0.1
-0.13
-0.09
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
- -
- -
- -
- -
- -
2004
- -
- -
- -
- -
- -
2005
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David E. Mai
Full Time Employees
47
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
336 Bollay Drive Santa Barbara CA United States of America 93117
IPO Date
Apr 11, 1995
Similar Companies
Venture Life Group plc (VLG.L)
Guangdong Lifestrong Pharmacy Co., Ltd. (301111.SZ)
BioSyent Inc. (RX.V)
Probi AB (publ) (PROB.ST)
MariMed Inc. (MRMD)
Anhui Huangshan Capsule Co., Ltd. (002817.SZ)
Business
Miravant Medical Technologies Inc. (MRVT) develops photodynamic therapy technologies under the PhotoPoint brand, utilizing light-activated drugs and associated medical devices to selectively destroy cancerous cells and treat various diseases while sparing healthy tissue. Founded in 1989 and headquartered in Santa Barbara, California, the company focuses on pharmaceutical research and development in the biotechnology sector, targeting ophthalmology, dermatology, cardiology, and oncology markets primarily in the United States. Its core products include PHOTREX (rostaporfin) for wet age-related macular degeneration; MV9411, a photoreactive drug for plaque psoriasis; MV0633 for atherosclerosis, vulnerable plaque, and restenosis; MV2101 for vascular access graft disease in hemodialysis patients; MV6401 for solid tumors; and light-producing and light-delivery devices integral to PhotoPoint procedures. In recent years, key assets including the REM-001 Therapy and related intellectual property originally developed by Miravant have been acquired by Adgero Biopharmaceuticals Holdings Inc., marking a significant technology transfer and operational shift as the company maintains its OTC-traded status amid limited active development updates.